#HSE #HealthServiceExecutive #Ireland #hidradenitissuppurativa #HS #axialspondyloarthritis #axSpA #Bimekizumab #BIMZELEX #NadegeFeeser #Immunology #UCB #chronicdiseases #BrianKirby #Dermatology #HSpatients #phase3studies #clinicaltrial #BEHEARD1 #BEHEARD2 #moderatetosevereHS
zurl.co/NrDNa